Revenue
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2022
2023
2024
2025
Ernexa Therapeutics Inc. (ERNA)
Price$4.41Cached quote
Net income
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $582,000 | $68,000 | $0 | — | $5.8M | $19.8M | $23.3M | $21.3M | $22.3M | $24.5M | $26.0M | $23.7M | $24.1M | $23.9M | $25.3M |
| Gross profit | $0 | $486,000 | −$168,000 | $0 | — | — | — | — | — | — | — | — | — | — | — | — |
| Gross margin | — | 83.51% | −247.06% | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Research & development | $4.2M | $4.6M | $5.9M | $10.4M | $12.7M | $4.0M | $26,000 | $72,000 | $139,000 | — | — | — | — | — | — | — |
| Operating expenses | $9.3M | $16.2M | $21.0M | $33.2M | $113.7M | $7.2M | $21.6M | $23.1M | $22.7M | $24.6M | $31.4M | $30.8M | $24.9M | $25.1M | $27.1M | $25.6M |
| Operating income | −$9.3M | −$15.7M | −$21.1M | −$33.2M | −$113.7M | −$7.2M | −$1.8M | $203,000 | −$1.4M | −$2.3M | −$6.9M | −$4.7M | −$1.1M | −$1.1M | −$3.3M | −$325,000 |
| Operating margin | — | −2,693.13% | −31,080.88% | — | — | −124.97% | −8.90% | 0.87% | −6.59% | −10.21% | −28.12% | −18.21% | −4.71% | −4.41% | −13.72% | −1.28% |
| EBITDA | −$9.3M | −$15.5M | −$21.1M | −$33.1M | −$113.6M | −$7.2M | $1.1M | $3.0M | $915,000 | $609,000 | −$3.8M | −$2.0M | $1.7M | $1.8M | −$16,000 | $2.9M |
| EBITDA margin | — | −2,669.24% | −30,957.35% | — | — | −123.28% | 5.63% | 12.71% | 4.30% | 2.73% | −15.46% | −7.67% | 7.28% | 7.55% | −0.07% | 11.37% |
| Net income | −$14.1M | −$44.5M | −$21.7M | −$24.6M | −$122.5M | −$7.3M | −$2.0M | −$259,000 | −$1.1M | −$2.9M | −$7.2M | −$5.0M | −$1.1M | −$995,000 | −$3.4M | −$400,000 |
| Net profit margin | — | −7,652.75% | −31,864.71% | — | — | −125.71% | −10.34% | −1.11% | −5.06% | −13.10% | −29.47% | −19.31% | −4.43% | −4.13% | −14.32% | −1.58% |
| Basic EPSper basic share | -$56.00 | -$1,224.00 | -$1,530.00 | -$3,022.50 | -$21,228.75 | -$3,075.00 | -$10,800.00 | -$1,500.00 | -$6,750.00 | -$23,100.00 | -$58,950.00 | -$45,000.00 | -$7,500.00 | -$7,500.00 | -$45,000.00 | -$7,500.00 |
| Diluted EPSper diluted share | -$56.00 | -$1,224.00 | -$1,530.00 | -$3,022.50 | -$21,228.75 | -$3,075.00 | -$10,800.00 | -$1,500.00 | -$6,750.00 | -$23,100.00 | -$58,950.00 | -$45,000.00 | -$7,500.00 | -$7,500.00 | -$45,000.00 | -$7,500.00 |
Owners
Reported shareholders
1.29%of listed shares
CITADEL ADVISORS LLC15.1K shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
Cherington Charles | —6.78M shares |
CITADEL ADVISORS LLC | 1.29%15.1K shares |
VANGUARD FIDUCIARY TRUST CO | 0.71%8.34K shares |
Dauntless Investment Group, LLC | 0.51%6K shares |
VANGUARD CAPITAL MANAGEMENT LLC | 0.49%5.68K shares |
Tradewinds Capital Management, LLC | 0.03%361 shares |
Gurrola Sandra M | ≈<0.01%110 shares |
BlackRock, Inc. | <0.01%33 shares |
ASSETMARK, INC | <0.01%5 shares |
BNP PARIBAS FINANCIAL MARKETS | <0.01%1 shares |
SBI Securities Co., Ltd. | <0.01%1 shares |
Percentages use 1.17M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Feb 10, 2026Form 4 | Cherington CharlesTenPercentOwner | BuyCommon Stock | 4.00M | $0.50 | $2.00M | 6.78M |
| Feb 10, 2026Form 4 | Cherington CharlesTenPercentOwner | BuyWarrants to Purchase Common Stock · derivative | 4.00M | — | — | 4.00M |
| Jun 9, 2025Form 4 | Cherington CharlesTenPercentOwner | BuyCommon Stock | 21.24M | $0.10 | $2.12M | 41.66M |
| Apr 2, 2025Form 4 | Cherington CharlesTenPercentOwner | BuyCommon Stock | 3.77M | $0.10 | $376.8K | 20.40M |
| Oct 29, 2024Form 4 | Cherington CharlesTenPercentOwner | BuyCommon Stock | 1.56M | — | — | 13.81M |